Income Statement Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:27:33 2025-01-22 pm EST			5-day change	1st Jan Change
56.95 ^USD	-0.16%		+1.80%	+0.63%

Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT
Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT

c0be5d618d8b.q8TJqer1-n_0mOyT1sFNrLG9AWyezS-xk6tvSoyNRYw.zLXk3auUkzCbyYfkhqwY1uT2WDjEgxmJ5uwpELm6AuvA9KbNoY-lS6fQtQ

Published financial data: BRISTOL-MYERS SQUIBB COMPANY

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	26.14B	42.52B	46.38B	46.16B	45.01B
Total Revenues	26.14B	42.52B	46.38B	46.16B	45.01B
Cost of Goods Sold, Total	7.22B	8.47B	9.34B	9.78B	10.52B
Gross Profit	18.92B	34.04B	37.05B	36.38B	34.49B
Selling General & Admin Expenses, Total	4.8B	7.37B	7.67B	7.7B	7.68B
R&D Expenses	5.89B	9.24B	9.53B	9.2B	9.11B
Amortization of Goodwill and Intangible Assets - (IS)	1.14B	9.69B	10.02B	9.6B	9.05B
Other Operating Expenses, Total	11.82B	26.29B	27.23B	26.5B	25.84B
Operating Income	7.1B	7.75B	9.82B	9.88B	8.65B
Interest Expense, Total	-656M	-1.38B	-1.29B	-1.15B	-1.16B
Interest And Investment Income	464M	121M	39M	171M	449M
Net Interest Expenses	-192M	-1.26B	-1.25B	-982M	-712M
Income (Loss) On Equity Invest.	-4M	72M	231M	-108M	-38M
Currency Exchange Gains (Loss)	-13M	23M	21M	96M	160M
Other Non Operating Income (Expenses)	1.39B	1.48B	1.66B	1.82B	2.08B
EBT, Excl. Unusual Items	8.28B	8.07B	10.48B	10.7B	10.14B
Restructuring Charges	-674M	-690M	-187M	-144M	-535M
Merger & Related Restructuring Charges	-1.79B	-4B	-831M	-863M	-326M
Gain (Loss) On Sale Of Investments	196M	1.16B	514M	-693M	-122M
Gain (Loss) On Sale Of Assets	1.17B	62M	9M	211M	-
Asset Writedown	-47M	-1.07B	-1.16B	-98M	-107M
In Process R&D Expenses	-	-11.44B	-	-815M	-913M
Legal Settlements	-77M	194M	-82M	-178M	-10M
Other Unusual Items	-2.08B	846M	-647M	-410M	313M
EBT, Incl. Unusual Items	4.98B	-6.87B	8.1B	7.71B	8.44B
Income Tax Expense	1.52B	2.12B	1.08B	1.37B	400M
Earnings From Continuing Operations	3.46B	-9B	7.01B	6.34B	8.04B
Net Income to Company	3.46B	-9B	7.01B	6.34B	8.04B
Minority Interest	-21M	-20M	-20M	-18M	-15M
Net Income - (IS)	3.44B	-9.02B	6.99B	6.33B	8.02B
Net Income to Common Incl Extra Items	3.44B	-9.02B	6.99B	6.33B	8.02B
Net Income to Common Excl. Extra Items	3.44B	-9.02B	6.99B	6.33B	8.02B
Per Share Items
Net EPS - Basic	2.02	-3.99	3.15	2.97	3.88
Basic EPS - Continuing Operations	2.02	-3.99	3.15	2.97	3.88
Basic Weighted Average Shares Outstanding	1.7B	2.26B	2.22B	2.13B	2.07B
Net EPS - Diluted	2.01	-3.99	3.12	2.95	3.86
Diluted EPS - Continuing Operations	2.01	-3.99	3.12	2.95	3.86
Diluted Weighted Average Shares Outstanding	1.71B	2.26B	2.24B	2.15B	2.08B
Normalized Basic EPS	3.02	2.22	2.94	3.13	3.06
Normalized Diluted EPS	3.01	2.22	2.91	3.11	3.04
Dividend Per Share	1.68	1.84	2.01	2.19	2.31
Payout Ratio	77.9	-45.2	62.85	73.24	59.12
American Depositary Receipts Ratio (ADR)	1	1	1	1	1
Supplemental Items
EBITDA	8.78B	18.18B	20.58B	20.16B	18.42B
EBITA	8.36B	17.65B	20.02B	19.58B	17.85B
EBIT	7.1B	7.75B	9.82B	9.88B	8.65B
EBITDAR	8.93B	18.44B	20.85B	20.45B	18.82B
Total Revenues (As Reported)	26.14B	42.52B	46.38B	46.16B	45.01B
Effective Tax Rate - (Ratio)	30.45	-30.91	13.39	17.74	4.74
Current Domestic Taxes	1B	1.24B	1.88B	3.02B	2.74B
Current Foreign Taxes	1.44B	-104M	598M	1.09B	943M
Total Current Taxes	2.44B	1.14B	2.48B	4.11B	3.69B
Deferred Domestic Taxes	-113M	229M	-1.26B	-2.89B	-2.34B
Deferred Foreign Taxes	-811M	754M	-138M	151M	-949M
Total Deferred Taxes	-924M	983M	-1.39B	-2.74B	-3.29B
Normalized Net Income	5.15B	5.02B	6.53B	6.67B	6.32B
Interest Capitalized	-	-	-	-	-
Non-Cash Pension Expense	1.61B	-6M	-23M	27M	11M
Supplemental Operating Expense Items
Advertising Expense	633M	990M	1.3B	1.3B	1.4B
Selling and Marketing Expenses	633M	990M	1.3B	1.3B	1.4B
Research And Development Expense From Footnotes	6.15B	22.58B	11.35B	10.32B	10.21B
Net Rental Expense, Total	156M	259M	274M	293M	405M
Imputed Operating Lease Interest Expense	29.82M	57.68M	58.22M	62.55M	91.36M
Imputed Operating Lease Depreciation	126M	201M	216M	230M	314M
Stock-Based Comp., COGS (Total)	19M	37M	57M	41M	51M
Stock-Based Comp., R&D Exp. (Total)	115M	339M	272M	221M	252M
Stock-Based Comp., SG&A Exp. (Total)	162M	332M	241M	195M	215M
Stock-Based Comp., Other (Total)	145M	71M	13M	-	-
Total Stock-Based Compensation	441M	779M	583M	457M	518M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	12.35B	14.55B	13.98B	9.12B	11.46B
Short Term Investments	3.05B	1.9B	3.24B	130M	816M
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	15.39B	16.45B	17.22B	9.25B	12.28B
Accounts Receivable, Total	7.68B	8.5B	9.73B	10.39B	11.34B
Other Receivables	-	-	2.79B	3.55B	3.93B
Total Receivables	7.68B	8.5B	12.52B	13.94B	15.26B
Inventory	4.29B	2.07B	2.1B	2.34B	2.66B
Prepaid Expenses	-	-	-	-	-
Deferred Tax Assets Current	-	-	-	-	-
Restricted Cash	-	89M	140M	148M	55M
Other Current Assets, Total	1.98B	3.08B	1.29B	1.6B	1.51B
Total Current Assets	29.35B	30.19B	33.26B	27.27B	31.77B
Gross Property Plant And Equipment	10.91B	10.33B	11B	11.64B	12.84B
Accumulated Depreciation	-3.96B	-3.58B	-4.03B	-4.16B	-4.8B
Net Property Plant And Equipment	6.96B	6.74B	6.97B	7.48B	8.04B
Long-term Investments	4.17B	4.51B	2.71B	2.19B	2.06B
Goodwill	22.49B	20.55B	20.5B	21.15B	21.17B
Other Intangibles, Total	63.97B	53.24B	42.53B	35.86B	27.07B
Accounts Receivable Long-Term	-	-	-	-	-
Deferred Tax Assets Long-Term	510M	1.16B	1.44B	1.34B	2.77B
Deferred Charges Long-Term	-	-	248M	496M	413M
Other Long-Term Assets, Total	2.5B	2.08B	1.66B	1.04B	1.87B
Total Assets	130B	118B	109B	96.82B	95.16B
Liabilities
Accounts Payable, Total	2.44B	2.71B	2.95B	3.04B	3.26B
Accrued Expenses, Total	7.97B	9.42B	9.94B	10.24B	11.04B
Short-term Borrowings	583M	340M	184M	367M	246M
Current Portion of Long-Term Debt	2.76B	2B	4.76B	3.9B	2.87B
Current Portion of Leases	133M	164M	169M	136M	162M
Current Income Taxes Payable	1.52B	647M	754M	942M	1.37B
Unearned Revenue Current, Total	-	-	-	-	-
Other Current Liabilities	2.9B	3.8B	3.11B	3.27B	3.31B
Total Current Liabilities	18.3B	19.08B	21.87B	21.89B	22.26B
Long-Term Debt	43.39B	48.35B	39.6B	35.16B	36.71B
Long-Term Leases	672M	833M	874M	1.26B	1.53B
Unearned Revenue Non Current	424M	357M	326M	283M	300M
Pension & Other Post Retirement Benefits	725M	899M	654M	402M	480M
Deferred Tax Liability Non Current	6.45B	5.41B	4.5B	2.17B	338M
Other Non Current Liabilities	8.28B	5.68B	5.48B	4.54B	4.05B
Total Liabilities	78.25B	80.6B	73.31B	65.7B	65.67B
Common Stock, Total	292M	292M	292M	292M	292M
Additional Paid In Capital	43.71B	44.32B	44.36B	45.16B	45.68B
Retained Earnings	34.47B	21.28B	23.82B	25.5B	28.77B
Treasury Stock	-25.36B	-26.24B	-31.26B	-38.62B	-43.77B
Comprehensive Income and Other	-1.52B	-1.84B	-1.27B	-1.28B	-1.55B
Total Common Equity	51.6B	37.82B	35.95B	31.06B	29.43B
Minority Interest	100M	60M	60M	57M	55M
Total Equity	51.7B	37.88B	36.01B	31.12B	29.48B
Total Liabilities And Equity	130B	118B	109B	96.82B	95.16B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.26B	2.24B	2.18B	2.1B	2.02B
ECS Total Common Shares Outstanding	2.25B	2.24B	2.18B	2.1B	2.02B
Book Value / Share	22.92	16.85	16.52	14.81	14.56
Tangible Book Value	-34.86B	-35.97B	-27.08B	-25.95B	-18.81B
Tangible Book Value Per Share	-15.49	-16.03	-12.45	-12.37	-9.31
Total Debt	47.54B	51.68B	45.6B	40.82B	41.52B
Net Debt	31.38B	34.8B	28.38B	31.57B	28.88B
Debt Equivalent of Unfunded Proj. Benefit Obligation	404M	435M	120M	-51M	26M
Debt Equivalent Oper. Leases	1.25B	2.07B	2.19B	2.34B	3.24B
Minority Interest, Total (Incl. Fin. Div)	100M	60M	60M	57M	55M
Equity Method Investments, Total	429M	549M	666M	546M	542M
Account Code - Inventory Valuation	6	6	6	6	6
Inventories - Raw Materials, Total	-	-	-	-	-
Inventories - Work In Process, Total	-	-	-	-	-
Inventories - Finished Goods, Total	-	-	-	-	-
Land - (BS)	187M	189M	169M	162M	162M
Buildings, Total	6.34B	5.73B	5.9B	5.92B	6.5B
Machinery, Total	3.16B	3.06B	3.25B	3.28B	3.72B
Full Time Employees	30K	30.25K	32.2K	34.3K	34.1K
Accumulated Allowance for Doubtful Accounts (Supple)	21M	18M	21M	22M	23M

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	3.44B	-9.02B	6.99B	6.33B	8.02B
Depreciation & Amortization - CF	421M	533M	557M	582M	569M
Amortization of Goodwill and Intangible Assets - (CF)	1.26B	9.9B	10.2B	9.7B	9.2B
Depreciation & Amortization, Total	1.68B	10.43B	10.76B	10.28B	9.77B
Minority Interest in Earnings - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	-1.86B	-699M	-684M	-231M	-22M
(Gain) Loss on Sale of Investments - (CF)	-279M	-1.23B	-745M	801M	160M
Asset Writedown & Restructuring Costs	332M	12.69B	1.21B	184M	297M
Stock-Based Compensation (CF)	441M	779M	583M	457M	518M
Other Operating Activities, Total	1.25B	105M	-654M	-2.52B	-2.97B
Change In Accounts Receivable	752M	-646M	-1.05B	-663M	-995M
Change In Inventories	463M	2.67B	13M	-69M	-751M
Change In Accounts Payable	229M	188M	245M	109M	198M
Change in Unearned Revenues	12M	-	-	-	-
Change In Income Taxes	907M	-2.3B	-1.06B	-1.42B	-603M
Change in Other Net Operating Assets	702M	1.07B	606M	-183M	237M
Cash from Operations	8.07B	14.05B	16.21B	13.07B	13.86B
Capital Expenditure	-836M	-753M	-973M	-1.12B	-1.21B
Cash Acquisitions	-24.63B	-13.08B	-1.61B	-4.29B	-1.17B
Divestitures	15.85B	870M	748M	1.3B	909M
Investment in Marketable and Equity Securities, Total	-152M	2.11B	1.3B	3.04B	-826M
Cash from Investing	-9.77B	-10.86B	-538M	-1.06B	-2.3B
Short Term Debt Issued, Total	131M	-	-	194M	-
Long-Term Debt Issued, Total	26.78B	6.94B	-	5.93B	4.46B
Total Debt Issued	26.91B	6.94B	-	6.12B	4.46B
Short Term Debt Repaid, Total	-	-267M	-160M	-	-120M
Long-Term Debt Repaid, Total	-9.26B	-2.75B	-6.02B	-11.43B	-3.88B
Total Debt Repaid	-9.26B	-3.02B	-6.18B	-11.43B	-4B
Issuance of Common Stock	-	-	-	-	-
Repurchase of Common Stock	-7.3B	-1.55B	-6.29B	-8B	-5.16B
Common Dividends Paid	-2.68B	-4.08B	-4.4B	-4.63B	-4.74B
Common & Preferred Stock Dividends Paid	-2.68B	-4.08B	-4.4B	-4.63B	-4.74B
Other Financing Activities, Total	-53M	542M	641M	984M	27M
Cash from Financing	7.62B	-1.15B	-16.22B	-16.96B	-9.42B
Foreign Exchange Rate Adjustments	-9M	111M	-102M	-33M	45M
Net Change in Cash	5.91B	2.15B	-657M	-4.99B	2.19B
Supplemental Items
Cash Interest Paid	414M	1.6B	1.5B	1.4B	1.2B
Cash Income Tax Paid (Refund)	1.5B	3.4B	3.5B	5.4B	4.3B
Levered Free Cash Flow	6.18B	16.41B	13.57B	13.83B	13.78B
Unlevered Free Cash Flow	6.59B	17.27B	14.38B	14.56B	14.51B
Change In Net Working Capital	-870M	-1.97B	2.12B	1.24B	-21M
Net Debt Issued / Repaid	17.65B	3.93B	-6.18B	-5.31B	456M

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	5.38	3.9	5.39	5.99	5.63
Return on Total Capital	7.35	5.13	7.17	8.04	7.56
Return On Equity %	10.51	-20.08	18.99	18.91	26.53
Return on Common Equity	10.48	-20.16	18.96	18.88	26.53
Margin Analysis
Gross Profit Margin %	72.38	80.07	79.87	78.81	76.63
SG&A Margin	18.36	17.33	16.54	16.69	17.06
EBITDA Margin %	33.57	42.77	44.37	43.68	40.93
EBITA Margin %	31.96	41.51	43.16	42.42	39.66
EBIT Margin %	27.16	18.23	21.17	21.4	19.22
Income From Continuing Operations Margin %	13.23	-21.16	15.12	13.75	17.86
Net Income Margin %	13.15	-21.2	15.08	13.71	17.83
Net Avail. For Common Margin %	13.15	-21.2	15.08	13.71	17.83
Normalized Net Income Margin	19.72	11.81	14.07	14.45	14.05
Levered Free Cash Flow Margin	23.63	38.6	29.26	29.97	30.62
Unlevered Free Cash Flow Margin	25.2	40.63	31.01	31.53	32.23
Asset Turnover